



Revolutionizing indoor health through *light*

INVESTOR PRESENTATION

TSX-V : UVC

OTCQB : FUVCF

September 2026

Important disclosures.

FORWARD-LOOKING INFORMATION

This presentation contains "forward-looking information" within the meaning of applicable Canadian securities laws and "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 (collectively, "forward-looking statements"). All statements other than statements of historical fact are forward-looking, including, without limitation, statements regarding product development plans, regulatory pathways, market opportunity, manufacturing capacity, partnership prospects, Far-UVC commercialization timelines, and the company's capital structure.

Forward-looking statements are based on assumptions and estimates management believes reasonable as of the date hereof. Actual results may differ materially due to risks including, but not limited to, regulatory delays, product development risk, competitive pressure, supply-chain disruption, customer adoption rates, capital market conditions, and the risks set forth in the company's continuous disclosure record on SEDAR+. The company undertakes no obligation to update forward-looking statements except as required by law.

NON-IFRS MEASURES

Certain financial measures referenced herein, including target gross margin, target unit pricing, serviceable addressable market, and bottom-up revenue path, are not recognised under International Financial Reporting Standards. Such measures do not have standardised meanings under IFRS and may not be comparable to similarly titled measures presented by other issuers.

INDUSTRY AND MARKET DATA

Market data, statistics, and forecasts cited herein are derived from third-party sources, internal estimates, and management assumptions. While the company believes such information to be reliable, it has not been independently verified. Statements regarding market size, penetration rates, competitive positioning, and the performance of competing products reflect management's views and may not be representative of actual outcomes. Independent third-party validation referenced, including the University of Leeds aerobiology study, reflects testing conducted under specified laboratory conditions; real-world performance may vary.

NO OFFER OR SOLICITATION

This presentation is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security in any jurisdiction in which such offer or solicitation would be unlawful. Any offer or sale of securities will be made only by means of a prospectus, offering memorandum, or subscription agreement filed or delivered in accordance with applicable securities laws.

U.S. SECURITIES ACT RESTRICTIONS AND CONFIDENTIALITY

The securities of the company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S) absent registration or an applicable exemption. This presentation is strictly confidential; reproduction or distribution is prohibited without prior written consent.

We solved fire. We solved water. We never solved air.

Every other shared risk got permanent infrastructure. Air is still improvised.



FIRE

Building codes.
Automatic sprinklers.
Smoke alarms.

Solved



WATER

Municipal treatment.
Sanitation systems.
Safe water on tap.

Solved



AIRBORNE PATHOGENS

Continuous pathogen reduction
built into occupied spaces.

Unsolved

Shared air still has no equivalent layer.

THE PEOPLE BEHIND THE OPPORTUNITY



These are not just buildings. They are where life happens.



SCHOOLS

Your child
in a classroom.



SENIOR CARE

Your grandparents
in senior care.



AVIATION

Your family
on a plane.



CRUISES

Your next holiday
on a cruise ship.

The ambition: make protection part of the places we already trust.

THE GLOBAL HEALTHCARE BURDEN



People go into hospital to get well.

Around

1 in 10

patients is affected by a healthcare-associated infection.

Protection should not end at the hospital door.



136M

healthcare-associated antibiotic-resistant infections estimated worldwide each year.

When an infection resists treatment, avoiding it matters even more.

The cost does not stop at the bedside.

US\$412B

Annual treatment expenses

For resistant bacterial infections.

Modeled to 2035

US\$443B

Annual productivity losses

From illness and mortality.

Modeled to 2035

KEEP EACH NUMBER IN CONTEXT

- Modeled global totals to 2035 under then-current action levels.
- Forecasts, not current spending or product savings.
- Not additive with the HAI figures.
- Not an addressable market.

Projected worldwide burden up to 2035.

A major economic and human cost.

Healthcare-acquired infections are a significant, preventable burden on Canada's healthcare system.



473,590

Healthcare-acquired infections a year.



33,151

Associated deaths a year.



C\$29.3B

Estimated annual economic burden.

C\$9.47B treatment costs
C\$19.85B lost hospital bed capacity

Infection prevention is a high-value investment.

Even a modest reduction in infections frees up critical hospital capacity, improves patient outcomes and generates meaningful economic value.

ILLUSTRATIVE VALUE OF PREVENTED INFECTIONS

At \$20,000 per infection avoided. Actual value varies by infection type and setting.

Infections avoided	5	10	25	50
Estimated value	\$100,000	\$200,000	\$500,000	\$1,000,000

1 Fewer infections, lives saved

2 Lower treatment costs

3 More beds and capacity

4 Stronger economic returns

THE PREVENTION CASE



The money goes to treatment. The leverage is in prevention.



AFTER INFECTION

Help the patient recover.

Diagnosis. Appropriate treatment. Responsible antibiotic use.



BEFORE EXPOSURE

Reduce pathogens in shared air.

Add engineered UV to ventilation, filtration and other infection controls.

Illumisoft's role: help make the environment part of prevention.

The pressure to act is building.

Standards, procurement, liability and preparedness, 2024 to 2026.

1

Indoor air is a health crisis

HEALTH CRISIS

Indoor transmission drives the burden, and clean-air expectations have moved.

2

Standards are tightening

STANDARDS

WHO and CDC raised clean-air targets. ASHRAE 241 sets new clean-airflow rules.

3

Canada moved first on UV

CANADA FIRST

CSA Z8000:24 adds annexes on supplemental disinfection technologies, and CSA Z317.12:25 addresses UV in healthcare facilities, ahead of global adoption.

4

Liability drives urgency

PROCUREMENT

Procurement is converting from awareness into signed contracts.

GLOBAL COMPETITIVE POSITION



Built for global leadership.




SaniLume

COMMERCIAL UPPER ROOM GUV

ACTIVE

Best at Leads

Best UV device tested in the Leeds chamber.



SaniLux

FAR-UVC IN DEVELOPMENT

COMING SOON

70x output

Against the stated excimer benchmark.



ECOWing

COMMERCIAL LIGHTING

REVENUE PRODUCING

34 of 50

Top DLC products in its category.

\$248B+

Market opportunity

20

Granted U.S. patents

99.7%

Chamber pathogen reduction

10+

Verticals served

Partners in the mission. Invested in its future.



Chris Anderson
RESILIENCE RESERVE / TED

"This could greatly enhance social resilience at all levels of global income."

Helped take TED Talks to a worldwide audience.



Rob Reid
RESILIENCE RESERVE / RHAPSODY / STRATEGIC
ADVISOR

"Far-UVC is the most promising biosecurity technology I have encountered in two decades of investing at the frontier of science and venture."

Entrepreneur, technology investor and Illumisoft strategic advisor.

19.43%

Resilience Reserve
Ownership

A century of science. A new level of engineering.

1937

School experiments

Upper-room UV was being studied in classrooms.

1994

CDC guidance

UVGI appeared in healthcare TB-control guidance.

2022

SaniLume testing

The University of Leeds tested Illumisoft's device.

CATEGORY EVIDENCE FOR FAR-UVC, PRINCIPALLY AT 222 NM

STUDY DESCRIBED

SOURCE-REPORTED FINDING

INTERPRETATION BOUNDARY

2020 | Columbia

99.9% inactivation of aerosolized coronaviruses

222 nm study conditions, not a SaniLux device result

2022 | Room-sized chamber

98.4% reduction in airborne S. aureus, 184 eACH

Experimental room and specified exposure conditions

2023 | 66-week mouse study


No increased skin cancer or abnormal growths reported

Animal observations, not proof of long-term human safety

Treat the air while the room is in use.

254 nm

UPPER-ROOM GUV



1 Position


UV is mounted above head height, so occupants never meet the beam.

2 Circulate


Fans draw room air continuously through the germicidal field.

3 Repeat


The room keeps operating below while the air above is treated.




Aerosol Pathogens Exhaled




Modeling of Pathogen Spread



Sanilume



UVC Energy Field



CFD aerosol modelling

Pathogens spread through a classroom without the device. The upper-room field treats the air above occupants.

Best in the Leeds chamber.

99.7%

P. aeruginosa reduction
in laboratory chamber testing.



The best performing UV device that has been tested in the aerobiology chamber at the University of Leeds to date.

Dr. Louise Fletcher
University of Leeds / August 2022

LEEDS CHAMBER ORGANISM	RELEVANCE DESCRIBED IN SOURCE	REDUCTION	EACH
Pseudomonas aeruginosa	Antibiotic-resistant / HAI organism	99.7%	1,994
Staphylococcus aureus	MRSA family, surgical-site pathogen	99.2%	744
Phi-6 bacteriophage	Enveloped RNA virus, COVID surrogate	99.1%	661

A hospital program with meaningful scale.

1,500

Budgeted SaniLume units
across two hospital programs.

1,000

Winnipeg
Tertiary facility

500

BC + Fraser Health
Partnered study

STILL CONDITIONAL

- CHAIR sign-off
- \$200k funder deposit
- On-site audit
- Final scope, capped at budget

1

Signed LOI

2

CHAIR sign-off

3

\$200k funder deposit

4


On-site audit

A new source. A broader ambition.

216 nm

Proprietary nanoengineered Far-UVC.
Core IP owned by Illumisoft.

IN DEVELOPMENT / OWNED IP



254 nm SaniLume, upper-room GUV

Treat circulating air above occupants. Shipping today.



216 nm SaniLux, Far-UVC in development

Develop continuous disinfection for occupied spaces.

Designed to move beyond excimer.

70x

Power output

Against the stated excimer benchmark.

10,000+

Hours of product life

Company-stated development target.

Owned

Core Far-UVC IP

No third-party source licensing dependency claimed.

METRIC	CONVENTIONAL COMPARATOR IN SOURCE	SANILUX CLAIM / TARGET	OPEN ITEM
Power output	Milliwatt range	Watt range, 70x higher	Output configuration
Kill time	60 to 90 minutes per cycle	Under 1 minute at peak output	Occupied-space irradiance is lower
Product life	Approximately 1,000 hours	10,000+ hours	Test basis
Unit price	\$1,000 to \$5,000+	Deck ~\$350, site ~\$1,000	Currency and price basis
Roadmap	n/a	Deck Q1 2027, site Q3 2027 to Q1 2028	Management confirmation required

From breakthrough science to products built for real life.



Delivered through frog and Synapse, part of Capgemini.

EUR 22.5B

Global revenue
Full year 2025

417,600

People worldwide
As at 30 June 2026

50+

Countries
Global operations

1



Design for use

Industrial design and product forms for
real environments.

2



Engineer to build

Engineering architecture, supply chain
and manufacturing.

3



Prepare to launch

Prototypes, pilot readiness and launch
planning.

"We believe Illumisoft's far UVC technology represents an important scientific breakthrough."

Kaethe Henning / Director, Consumer HealthTech Business, Synapse, part of Capgemini

Blueprint makes the infrastructure case.



Far-UVC represents one of the highest-leverage funding opportunities in airborne disease and pandemic prevention that we are aware of.

Blueprint Biosecurity / Blueprint for Far-UVC, 2025

10:1

ROI cited for ASHRAE 241 clean-air compliance analyses

30 to 290x

Benefit-cost ratios cited for Far-UVC in public indoor spaces

34 of the top 50. In one portfolio.

167 lm/W of DLC-listed efficiency, engineered and manufactured in Ottawa.
The revenue base and the warm channel into both UV platforms.



REVENUE PRODUCING

167 lm/W Peak efficacy	60 to 75% Energy savings	5 min Install time	50,000 h Lifespan	17 Patents	40 to 55% Gross margin
--	--	--	---	----------------------------------	--

EXISTING LIGHTING RELATIONSHIPS



Start where the need is clear. Expand into everyday life.

\$9.7B

SaniLume

Hospital serviceable addressable market.

230K x 12 units. Source cites \$96M at 1%.

\$5.25B

SaniLux

Phase 1: hospitals and aviation.

Phase 2 schools and commercial, \$35B+. 30,000 aircraft x 20 units = 600K units.

~\$8B

ECOWing

North American LED retrofit market.

Top five players hold about 20%.

1

\$248B

Infection control, 2024

2

\$473B

By 2034

3

6.7%

Stated CAGR

4

5 to 30%


UV penetration

5

40 to 49%

N. America share

From Canadian execution to global scale.



THREE WAYS TO TURN ADOPTION INTO REVENUE

Sell efficient lighting. ECOWing commercial product sales. 40 to 55% gross margin reported	Sell upper-room GUV. SaniLume devices and institutional deployments. Active revenue product line	Sell Far-UVC direct. SaniLux product sales once development completes. In development, not yet commercial
---	---	--

Different relationships prove different things.




REGULATORY



R&D PARTNER



REAL ESTATE



REAL ESTATE



REAL ESTATE



FEDERAL



HOSPITAL PILOT



STANDARDS BODY



RANKINGS



COALITION



BOARD CONNECT



INDUSTRY AWARD

CATEGORY	ORGANIZATIONS NAMED IN SOURCE	MEANING RETAINED
Regulation / standards	Health Canada; CSA	Registration and standards references, not an endorsement or universal mandate
R&D / testing	NRC; University of Leeds	R&D and Workplace 3.0 context; device testing under stated conditions
Commercial relationships	QuadReal; BGO; Trioest; BGIS	Existing real-estate and lighting relationships, no GUV purchases inferred
Public sector / hospital	National Defence; Queensway Carleton Hospital	Federal relationship and hospital-pilot references, as labelled in the source
Commercialization	Capgemini; frog; Synapse	Product design, engineering and manufacturing-readiness work
Category / recognition	Blueprint; DLC; IES; Microbix	Advocacy; rankings; recognition; board connection, respectively

Science, commercialization and adoption.



Ehsan Agahi

CHIEF EXECUTIVE OFFICER

Zephyr Venture Partners. Biotech and life-sciences M&A.



Dr. Michael Johnson

CHIEF TECHNOLOGY OFFICER

Physics PhD, ASU. Former Motorola semiconductor. Architect of SaniLux.



Ali Pickett

CHIEF FINANCIAL OFFICER

15+ yrs financial leadership. Managed \$8B+ in assets. TSX-V experience.

BOARD AND ADVISORS



Brett Nicholds

STRATEGIC ADVISOR

Led Illumisoft from precommercialization to national distribution.



Cameron Groome

DIRECTOR

CEO Microbix Biosystems (TSX). Advised Global Affairs Canada.



Ryan Adam

DIRECTOR

Wellington DuPont. Former PMO Western Canada and Natural Resources.

Great technology must also get adopted.



Dr. Jonathan Ketcham

ILLUMISOFT STRATEGIC ADVISOR

Former White House Chief Healthcare Economist

2025 to 2026

- Distinguished Research Professor, Arizona State University
- Former Principal Economist, Amazon
- Founder, Margin Health
- PhD in Economics, Wharton

HIS ROLE AT ILLUMISOFT

Build the economic case and help navigate procurement, reimbursement and institutional adoption.

"The power of light to prevent disease is not just a beautiful metaphor, it is cutting-edge science."



Small-cap entry. Global infrastructure ambition.

ILLUMISOFT / TRADING TODAY

~C\$51M

Indicative basic market capitalization
46,173,389 shares x a C\$1.11 reference price, early September 2026. The shares are thinly traded and have ranged roughly C\$0.47 to C\$1.10 since listing, so this moves with the quote.

R-ZERO / HISTORICAL FINANCING

~C\$735M

Estimated 2023 post-money valuation
US\$526.9M at 16 September 2026 FX. US\$105M Series C, US\$170M+ raised in total.

WHAT EXECUTION MUST DELIVER

1

Convert the program

Finalize hospital scope and complete the conditional deployment steps.

2

Industrialize SaniLux

Complete product design, engineering and pilot readiness.

3

Launch, then scale

Validate the product and progress toward commercial launch.

Capitalization and capital deployment.

SHARES OUTSTANDING


Issued common shares	46,173,389
Options	3,540,000
Finder warrants	425,390

FULLY DILUTED

50,138,779

Per the fully diluted table in the 21 April 2026 qualifying transaction closing release.

USE OF PROCEEDS



Six reasons. Why Illumisoft.



1

Standards

Structural demand

CSA Z8000:24 and Z317.12:25 put engineered air disinfection in front of Canadian healthcare planners.



2

1,994 eACH

Validated performance

1,994 equivalent air changes per hour against P. aeruginosa, versus 0.003 to 17.1 for every other device tested.



3

70x

An unpriced option

70x the stated excimer benchmark, IP owned outright, carrying no value in the market capitalization.



4

C\$2.52M

Mission-aligned backers

Chris Anderson and Rob Reid subscribed through Resilience Reserve in December 2025.



5

US\$855B

Two existential tailwinds

Modeled annual treatment and productivity losses from resistant infections, to 2035.



6

1,500 units

An anchor already signed

Two CHAIR hospital programs budgeted under a signed LOI, against roughly C\$51M.

Safer air.
Better health.
Better future.



WEB

illumisoft.com

CONTACT

info@illumisoft.com

REGISTERED

Ottawa, Canada

LISTINGS

TSX-V : UVC | OTCQB : FUVCF